$SIGY

Sigyn Therapeutics, Inc.

CIK:0001642159|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Net revenues
Gross Profit
Operating expenses:
Marketing expenses	52	114	236	460
Stock based compensation	50,000	37,500	150,000	112,500
Research and development	29,681	206,161	46,004	679,183
General and administrative	306,796	564,683	1,205,861	1,249,089
Total operating expenses	386,529	808,458	1,402,101	2,041,232
Loss from operations	(386,529)	(808,458)	(1,402,101)	(2,041,232)
Other expense:
Other income			(5,797)
Modification of warrants		24,770	17,505	24,770
Inducement of preferred shares			845,901
Interest expense	2,024	850	3,345	2,931
Interest expense - debt discount	70,211	263,719	140,090	423,663
Interest expense - original issuance costs	119,739	99,126	295,109	324,798
Total other expense	191,974	388,465	1,296,153	776,162
Loss before income taxes	(578,503)	(1,196,923)	(2,698,254)	(2,817,394)
Income taxes
Net loss	$ (578,503)	$ (1,196,923)	$ (2,698,254)	$ (2,817,394)
Net loss per share, basic	$ (0.36)	$ (0.94)	$ (1.68)	$ (2.26)
Net loss per share, diluted	$ (0.36)	$ (0.94)	$ (1.68)	$ (2.26)
Weighted average number of shares outstanding, Basic	1,605,377	1,268,795	1,605,377	1,245,885
Weighted average number of shares outstanding, Diluted	1,605,377	1,268,795	1,605,377	1,245,885

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (578,503)	$ (668,564)	$ (1,196,923)	$ (758,088)	$ (2,698,254)	$ (2,817,394)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0		1,363		1,363	4,248
Stock based compensation					150,000	112,500
Accretion of debt discount					140,090	423,663
Accretion of original issuance costs					295,109	324,798
Modification of warrants			24,770		17,505	24,770
Inducement of preferred shares					845,901
Settlement of lease					(5,798)
Stock issued for services						214,550
Warrants issued for services						15,703
Changes in operating assets and liabilities:
Other current assets					8,997	2,053
Other assets					20,711
Accounts payable					165,220	149,997
Accrued payroll and payroll taxes					410,758	969,890
Other current liabilities					2,190	(6,996)
Net cash used in operating activities					(646,208)	(582,218)
Cash flows from financing activities:
Proceeds from short-term convertible notes					706,635	771,890
Proceeds from short-term promissory notes					13,000
Advance from shareholder						35,000
Repayments of advance from shareholder						(71,574)
Net cash provided by financing activities					719,635	735,316
Net increase in cash					73,427	153,098
Cash at beginning of period		$ 12,144		$ 11,690	12,144	11,690	$ 11,690
Cash at end of period	$ 85,571		$ 164,788		85,571	164,788	12,144
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Warrants issued to third parties in conjunction with debt issuance					414,687	390,637
Derivative liability in conjunction with debt issuance					181,362
Original issue discount issued in conjunction with debt					75,320	80,739
Original issue discount issued in conjunction with extension of debt					737,788	184,471
Common stock issued to third parties in conjunction with conversion of debt						707,730	$ 1,549,148
Preferred stock issued to third parties in conjunction with conversion of debt						841,419
Cancellation of common stock – related party						$ 7

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash	$ 85,571	$ 12,144
Other current assets		9,100
Total current assets	85,571	21,244
Property and equipment, net		9,685
Operating lease right-of-use assets, net		112,079
Other assets	50,000	70,711
Total assets	135,571	213,719
Current liabilities:
Accounts payable	773,604	608,384
Accrued payroll and payroll taxes	2,279,731	1,868,973
Short-term promissory notes, less unamortized debt issuance costs of $22,363 and $139,794, respectively	304,637	174,206
Convertible notes payable, less unamortized debt issuance costs of $319,593 and $130,252, respectively	446,225	1,891,736
Derivative liability	181,362
Current portion of operating lease liabilities		69,946
Other current liabilities	3,932	1,742
Total current liabilities	3,989,491	4,614,987
Long-term liabilities:
Long-term convertible notes payable, less unamortized debt issuance costs of $720,687 and $0, respectively, net of current	2,063,289
Operating lease liabilities, net of current portion		56,356
Total long-term liabilities	2,063,289	56,356
Total liabilities	6,052,780	4,671,343
Stockholders’ deficit:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 5,107 and 2,403 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
Common stock, $0.0001 par value, 100,000,000 shares authorized; 1,605,377 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	161	161
Additional paid-in capital	11,462,608	10,223,939
Accumulated deficit	(17,379,978)	(14,681,724)
Total stockholders’ deficit	(5,917,209)	(4,457,624)
Total liabilities and stockholders’ deficit	$ 135,571	$ 213,719